A novel protein-based anticancer drug encapsulating nanosphere: Apoferritin-doxorubicin complex

Journal of Biomedical Nanotechnology

Volumn 8, Issue 3, 2012, Pages 508-514

  Kilic, Mehmet A ^a   Ozlu, Erdal ^a   Calis, Sema ^b  

^a AKDENIZ UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cancer therapy; Doxorubicin; Drug delivery; Drug encapsulation; Ferritin; Nanosphere

Indexed keywords

ANTI-CANCER DRUG DELIVERY; ANTICANCER DRUG; APOFERRITIN; CANCER THERAPY; DOXORUBICIN; DRUG DELIVERY SYSTEM; DRUG ENCAPSULATION; DRUG LEAKAGE; DRUG MOLECULES; FERRITIN; INTERNAL CAVITIES; NANO-SIZE; NANOCARRIERS; POLYACRYLAMIDE GELS; PROTEIN CAGES;

DRUG DELIVERY; MOLECULES; NANOSPHERES; PROTEINS; SPHERES;

ENCAPSULATION;

APOFERRITIN; DOXORUBICIN; NANOCARRIER; NANOSPHERE; POLYACRYLAMIDE GEL;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG SOLUTION; ELECTROPHORESIS; ENCAPSULATION; NANOANALYSIS; PH;

ANTIBIOTICS, ANTINEOPLASTIC; APOFERRITINS; CRYSTALLIZATION; DELAYED-ACTION PREPARATIONS; DIFFUSION; DOXORUBICIN; MATERIALS TESTING; NANOCAPSULES; PARTICLE SIZE;

EID: 84862284153     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2012.1406     Document Type: Article

References (33)

1. F. Lacoeuille, E. Garcion, J. P. Benoit, and A. Lamprecht, Lipid nanocapsules for intracellular drug delivery of anticancer drugs. J. Nanosci. Nanotechnol. 7, 4612 (2007).
2. A. Estella-Hermoso de Mendoza, M. A. Campanero, F. Mollinedo, and M. J. Blanco-Prieto, Lipid nanomedicines for anticancer drug therapy. J. Biomed. Nanotechnol. 5, 323 (2009).
3. P. Menei, C. Montero-Menei, M. C. Venier, and J. P. Benoit, Drug delivery into the brain using poly(lactide-co-glycolide) microspheres. Expert. Opin. Drug. Deliv. 2, 363 (2005).
4. S. Jaracz, J. Chen, L. V. Kuznetsova, and I. Ojima, Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 13, 5043 (2005).
5. E. R. Gillies and J. M. Fréchet, Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today 10, 35 (2005).
6. H. Li and Z. M. Qian, Transferrin/transferrin receptor-mediated drug delivery. Med. Res. Rev. 22, 225 (2002).
7. A. Maham, Z. Tang, H. Wu, J. Wang, and Y. Lin, Protein-based nanomedicine platforms for drug delivery. Small 5, 1706 (2009).
8. P. M. Harrison, P. D. Artymiuk, G. C. Ford, J. M. Lawson, J. M. A. Smith, A. Treffry, and J. L. White, In Biominerilization Chem. and Biochem. Perspec. edited by S. Mann, J. Webb, R. J. P. Williams, VCH Verlagsgescllschaft, Weinham (1989), pp. 257-294.
9. P. Arosio, S. Levi, P. Santambrogio, A. Cozzi, A. Luzzago, G. Cesareni, and A. Albertini, Structural and functional studies of human ferritin H and L chains. Curr. Stud. Hematol. Blood Transfus. 58, 127 (1991).
10. J. Fisher, K. Devraj, J. Ingram, B. Slagle-Webb, A. B. Madhankumar, X. Liu, M. Klinger, I. A. Simpson, and J. R. Connor, Ferritin: A novel mechanism for delivery of iron to the brain and other organs. Am. J. Physiol. Cell. Physiol. 293, 641 (2007).
11. M. Worwood, Ferritin. Blood Rev. 4, 259 (1990).
12. P. Aisen, Ferritin receptors and the role of ferritin in iron transport. Targeted Diagn. Ther. 4, 339 (1991).
13. J. R. Burdo and J. R. Connor, Brain iron uptake and homeostatic mechanisms: An overview. BioMetals 16, 63 (2003).
14. Z. Yang, X. Wang, H. Diao, J. Zhang, H. Li, H. Sun, and Z. Guo, Encapsulation of platinum anticancer drugs by apoferritin. Chem. Commun. 33, 3453 (2007).
15. H. Wu, J. Wang, Z. Wang, D. R. Fisher, and Y. Lin, Apoferritin-templated yttrium phosphate nanoparticle conjugates for radioimmunotherapy of cancers. J. Nanosci. Nanotechnol. 5, 2316 (2008).
16. R. Xing, X. Wang, C. Zhang, Y. Zhang, Q. Wang, Z. Yang, and Z. Guo, Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin. J. Inorg. Biochem. 103, 1039 (2009).
17. M. Uchida, M. L. Flenniken, M. Allen, D. A. Willits, B. E. Crowley, S. Brumfield, A. F. Willis, L. Jackiw, M. Jutila, M. J. Young, and T. Douglas, Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles. J. Am. Chem. Soc. 128, 16626 (2006).
18. L. Turyanska, T. D. Bradshaw, J. Sharpe, M. Li, S. Mann, N. R. Thomas, and A. Patane, The biocompatibility of apoferritin-encapsulated PbS quantum dots. Small 5, 1738 (2009).
19. A. Jaaskelainen, T. Soukka, U. Lamminmaki, T. Korpimaki, and M. Virta, Development of a denaturation/renaturation-based production process for ferritin nanoparticles, Biotechnol. Bioeng 102, 1012 (2009).
20. M. Uchida, M. Terashima, C. H. Cunningham, Y. Suzuki, D. A. Willits, A. F. Willis, P. C. Yang, P. S. Tsao, M. V. McConnell, M. J. Young, and T. Douglas, A human ferritin iron oxide nano-composite magnetic resonance contrast agent. Magn. Reson. Med. 60, 1073 (2008).
21. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185 (2004).
22. G. Batist, G. Ramakrishnan, C. S. Rao, A. Chandrasekharan, J. Gutheil, T. Guthrie, P. Shah, A. Khojasteh, M. K. Nair, K. Hoelzer, K. Tkaczuk, Y. C. Park, and L. W. Lee, Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19, 1444 (2001).
23. D. K. Chang, C. Y. Chiu, S. Y. Kuo, W. C. Lin, A. Lo, Y. P. Wang, P. C. Li, and H. C. Wu, Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J. Biol. Chem. 284, 12905 (2009).
24. E. Simsek and M. A. Kilic, Magic ferritin: A novel chemotherapeutic encapsulation bullet. J. Magn. Magnetic. Materials 293, 509 (2005).
25. M. A. Kilic, S. Spiro, and G. R. Moore, Stability of a 24-meric homopolymer: Comparative studies of assembly-defective mutants of Rhodobacter capsulatus bacterioferritin and the native protein. Protein Sci. 12, 1663 (2003).
26. M. Gerl and R. Jaenicke, Assembly of apoferritin from horse spleen: Comparison of the protein in its native and reassembled state. Biol. Chem. Hoppe. Seyler. 368, 387 (1987).
27. S. C. Andrews, J. M. Smith, C. Hawkins, J. M. Williams, P. M. Harrison, and J. R. Guest, Overproduction, purification and characterization of the bacterioferritin of Escherichia coli and a C-terminally extended variant. Eur. J. Biochem. 213, 329 (1993).
28. R. R. Crichton and F. A. Bryce, Subunit interactions in horse spleen apoferritin: dissociation by extreme of Ph. Biochem. J. 133, 289 (1973).
29. J. M. Domínguez-Vera, Iron(III) complexation of Desferrioxamine B encapsulated in apoferritin. J. Inorg. Biochem. 98, 469 (2004).
30. J. Bouma, J. H. Beijnen, A. Bult, and W. J. Underberg, Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties. Pharm. Weekbl. Sci. 8, 109 (1986).
31. J. B. Chaires, N. Dattagupta, and D. M Crothers, Self-association of daunomycin. Biochemistry 21, 3927 (1982).
32. G. C. Ford, P. M. Harrison, D. W. Rice, J. M. Smith, A. Treffry, J. L. White, and J. Yariv, Ferritin: Design and formation of an iron-storage molecule. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 304, 551 (1984).
33. P. Santambrogio, S. Levi, P. Arosio, L. Palagi, G. Vecchio, D. M. Lawson, S. J. Yewdall, P. J. Artymiuk, P. Harrison, R. Japelli, and G. Cesareni, Evidence that a salt bridge in the light chain contributes to the physical stability difference between heavy and light human ferritins. Biochem. J. 322, 461 (1992).